Publications by authors named "S Kfir-Erenfeld"
Purpose: The use of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA CART was the first proof of concept for its applicability to AL. This report addresses the AL patient cohort treated to date within the phase Ia/Ib clinical trial (ClinicalTrials.
View Article and Find Full Text PDFHBI0101 is an academic chimeric antigen receptor T-cell (CART)-targeted to B-cell maturation antigen (BCMA) for the treatment of relapsed and refractory multiple myeloma (R/RMM) and light chain amyloidosis. Herein, we present the phase 1b/2 results of 50 heavily pretreated patients with R/RMM dosed with 800 × 106 CART cells. Inclusion criteria were relatively permissive (i.
View Article and Find Full Text PDFPurpose: Although chimeric antigen receptor T therapy (CAR-T) cells are an established therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models predicting outcome to identify patients who may benefit the most from CAR-T.
Patients And Methods: This is an international retrospective observational study including patients with RRMM infused with currently available commercial or academically produced anti-B-cell maturation antigen (BCMA) CAR-T. We describe characteristics and outcomes in Europe (n = 136) and the United States (n = 133).
Article Synopsis
- Mutations in T-cell receptor (TCR) signaling can lead to combined immunodeficiency (CID), highlighted by its effects on T-cell homeostasis and differentiation.
- This study focuses on two cousins with CID caused by a novel LCK gene mutation, which results in a truncated protein affecting T-cell function.
- The patients experienced early infections, showed reduced CD4 T-cell levels, and while TCR signaling was impaired, some mTOR signaling pathways remained active, allowing for limited differentiation of T-cells despite their dysfunctional performance.
Multiple myeloma (MM) is characterized by recurrent relapses. Consequently, patients receive multiple therapy lines, including alkylating agents and immune modulators, which have been associated with secondary malignancies such as myelodysplastic syndrome (MDS). Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cell (CART) therapy is efficacious in patients with relapsed/refractory (R/R) MM.
View Article and Find Full Text PDF